PHILADELPHIA--(BUSINESS WIRE)-- Iroko Pharmaceuticals, LLC announced on January 6, 2011 the results of its Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using its proprietary, patented nanotechnology. The comparator product used in this Phase I pharmacokinetic study of naproxen was identified as Naprosyn®. The comparator product used in the study was EC-Naprosyn®, a currently marketed enteric-coated brand of naproxen.
About Iroko Pharmaceuticals, LLC: Iroko is a pharmaceutical company committed to the development and commercialization of currently marketed pharmaceutical products in specialty therapeutic areas. Iroko is focused on the maximization of the revenue potential of currently marketed products through directed selling and marketing efforts and product-life-cycle management activities including development of new formulations to improve patient therapies. Iroko currently has three products under development, using iCeutica's proprietary SoluMatrix™ Platform nanotechnology. Iroko is headquartered in Philadelphia, PA.
EC-Naprosyn® and Naprosyn® are registered trademarks of Syntex Pharmaceuticals International Limited.
Phoenix IP Ventures
Lisa Gray, Managing Partner
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Research Other Science Science